An ultra-fast digital diffuse optical spectroscopic imaging system for neoadjuvant chemotherapy monitoring by Torjesen, Alyssa Ashley
Boston University
OpenBU http://open.bu.edu
Theses & Dissertations Boston University Theses & Dissertations
2016
An ultra-fast digital diffuse optical
spectroscopic imaging system for
neoadjuvant chemotherapy
monitoring
https://hdl.handle.net/2144/19470
Boston University
BOSTON UNIVERSITY 
 
COLLEGE OF ENGINEERING 
 
 
 
 
 
Thesis 
 
 
 
 
 
AN ULTRA-FAST DIGITAL DIFFUSE OPTICAL SPECTROSCOPIC IMAGING  
 
SYSTEM FOR NEOADJUVANT CHEMOTHERAPY MONITORING 
 
 
 
 
by 
 
 
 
 
ALYSSA TORJESEN 
 
B.S., Pepperdine University, 2010 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the 
 
requirements for the degree of 
 
Master of Science 
 
2016 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 © 2016 by 
  ALYSSA TORJESEN 
  All rights reserved 
Approved by 
 
 
 
 
 
 
 
First Reader 
   ______________________________________________ 
   Darren Roblyer, Ph.D. 
   Assistant Professor of Biomedical Engineering 
 
 
 
 
Second Reader 
   ______________________________________________ 
   Irving J. Bigio, Ph.D. 
   Professor of Biomedical Engineering 
Professor of Electrical and Computer Engineering 
Professor of Physics 
Professor of Medicine 
 
 
 
 
Third Reader 
   ______________________________________________ 
   Sergio Fantini, Ph.D. 
   Professor of Biomedical Engineering 
   Tufts University 
 
 
 
 
 
iv 
Acknowledgements 
 
 I would like to thank my advisor, Dr. Darren Roblyer, who sparked my 
interest in the world of diffuse optics. He has skillfully explained countless 
concepts to me about instrumentation and optics and has guided me through 
numerous design challenges with great patience. His passion for advancing 
optical technologies and improving cancer care is evident in his dedication to his 
students and research, and I am very fortunate to have been mentored by such 
an exceptional advisor.  
 I am grateful for the many contributions from the fellow graduate students 
in the Biomedical Optical Technologies Lab, including Raeef Istfan, Kavon 
Karrobi, Hannah Peterson, Syeda Tabassum, Fei Teng, and Yanyu Zhao. I am 
particularly grateful for Raeef’s help with instrumentation and Hannah’s help with 
measurements and data processing.  
 Those who have worked on the dDOSI project before me have laid the 
groundwork for a successful and powerful clinical instrument. I would like to 
thank Justin Jung, who studied undersampling as a viable direct sampling 
method for the dDOSI system. The 2013 Senior Design Group was instrumental 
in providing the hardware-integrated platform that is the basis of the dDOSI 
system. Finally, I would like to acknowledge all the hard work and patience of the 
members of the Electronics Design Facility, particularly Dan Gastler and Dean 
v 
DeCarli, who have helped with troubleshooting hardware challenges and with 
countless iterations of the firmware to perfect all signal generation and sampling. 
 I am grateful for my colleagues’ dedication to improving health that has 
allowed this project to be successful, and for the unconditional support of my 
family that has driven me to pursue my goals.  
  
  
vi 
AN ULTRA-FAST DIGITAL DIFFUSE OPTICAL SPECTROSCOPIC IMAGING 
 
SYSTEM FOR NEOADJUVANT CHEMOTHERAPY MONITORING 
 
ALYSSA TORJESEN 
 
ABSTRACT 
 
Up to 20% of breast cancer patients who undergo presurgical 
(neoadjuvant) chemotherapy have no response to treatment. Standard-of-care 
imaging modalities, including MRI, CT, mammography, and ultrasound, measure 
anatomical features and tumor size that reveal response only after months of 
treatment. Recently, non-invasive, near-infrared optical markers have shown 
promise in indicating the efficacy of treatment at the outset of the chemotherapy 
treatment. For example, frequency domain Diffuse Optical Spectroscopic 
Imaging (DOSI) can be used to characterize the optical scattering and absorption 
properties of thick tissue, including breast tumors. These parameters can then be 
used to calculate tissue concentrations of chromophores, including 
oxyhemoglobin, deoxyhemoglobin, water, and lipids. Tumors differ in hemoglobin 
concentration, as compared with healthy background tissue, and changes in 
hemoglobin concentration during neoadjuvant chemotherapy have been shown 
to correlate with efficacy of treatment. Using DOSI early in treatment to measure 
chromophore concentrations may be a powerful tool for guiding neoadjuvant 
chemotherapy treatment. 
Previous frequency-domain DOSI systems have been limited by large 
device footprints, complex electronics, high costs, and slow acquisition speeds, 
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all of which complicate access to patients in the clinical setting. In this work a 
new digital DOSI (dDOSI) system has been developed, which is relatively 
inexpensive and compact, allowing for use at the bedside, while providing 
unprecedented measurement speeds. The system builds on, and significantly 
advances, previous dDOSI setups developed by our group and, for the first time, 
utilizes hardware-integrated custom board-level direct digital synthesizers (DDS) 
and analog to digital converters (ADC) to generate and directly measure signals 
utilizing undersampling techniques. The dDOSI system takes high-speed optical 
measurements by utilizing wavelength multiplexing while sweeping through 
hundreds of modulation frequencies in tens of milliseconds. The new dDOSI 
system is fast, inexpensive, and compact without compromising accuracy and 
precision.  
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1 
Background 
 
Motivation 
  
Breast cancer is the most commonly occurring cancer in the United 
States, making up 14.6% of all cancer diagnoses[1]. A growing number of breast 
cancer patients undergo neoadjuvant chemotherapy (NAC) prior to mastectomy 
or lumpectomy in an effort to eliminate or reduce the size of the tumor and allow 
for a less invasive surgery. NAC response is typically categorized into three 
response groups—pathological complete response (pCR), partial response (PR), 
and no response (NR), where those with a pCR or PR tend to have increased 
long term survival[2], [3]. About 9–20% of women who undergo NAC fall into the 
NR group[4], [5], which can mean receiving months of toxic drugs with no 
reduction in tumor dimension.  
 Current standard of care breast cancer structural imaging modalities 
include x-ray mammography[6], MRI[6], [7], and ultrasound[6]. Each of these 
modalities has unique benefits in determining the location or morphology of the 
tumor, but it typically takes weeks to months of treatment to identify structural 
and anatomic changes in the tumor. Thus, a patient may undergo most or all of a 
NAC regimen before structural imaging would provide information as to whether 
or not the regimen is effective for that particular patient. Alternatively, functional 
imaging may allow for earlier time point detection of changes in the molecular 
makeup or metabolism of the tissue. PET-CT is a functional imaging method 
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sometimes employed in breast cancer monitoring, but it requires an exogenous 
contrast agent, which can be harmful to the patient. Diffuse optical imaging, 
instead, uses only non-ionizing radiation and can recover information about 
metabolism and chromophore concentrations, such as oxy- or deoxy-
hemoglobin, water, and lipid, in the tumor and surrounding tissue, making it 
possible to differentiate breast tumors from healthy tissue[8], [9].  
Previous studies have shown changes in chromophore concentrations in 
the first days or weeks of NAC may be predictive of pathological response. 
Cerussi et al.[10] and Soliman et al.[8] showed that a drop in deoxyhemoglobin 
concentration in the affected breast in the first weeks of therapy was associated 
with improved pathological response. Later, Roblyer et al.[11] saw an increase in 
oxyhemoglobin on the first day of treatment associated with pCR. Although the 
exact mechanism by which an increase in oxyhemoglobin in the first days of 
treatment affects NAC response warrants further investigation, the ability to 
detect chromophore concentrations at early time points in therapy may allow for 
individual NAC regimens to be altered as needed to provide the most effective 
treatment for each patient, minimizing unnecessary adverse side effects and 
improving long term survival.  
 
Diffuse Optical Spectroscopic Imaging Theory 
 
 Diffuse Optical Spectroscopic Imaging (DOSI) has been developed over 
the past three decades to characterize optical scattering and absorption and, in 
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turn, calculate chromophore concentrations in thick tissue[12], [13]. Diffuse 
optical imaging is categorized into three distinct measurement types: time 
domain, frequency domain, and continuous wave. Time domain measurements 
recover the most information about the tissue, but require complex 
instrumentation that comes at a high cost. Continuous wave measurement is the 
simplest of the diffuse optical techniques but, in turn, recovers the least 
information about the tissue. Frequency domain diffuse optical imaging is a 
compromise between the other measurement types in that it recovers more 
information about the tissue than does continuous wave, yet the instrumentation 
is simpler compared to that required for time domain measurements. This work 
focuses on frequency domain DOSI to recover tissue optical properties. 
As photons travel through tissue, they undergo both absorption by 
chromophores and 
scattering when 
encountering changes in 
refractive index. Both 
scattering and absorption 
attenuate the measured 
intensity of light at the 
detector position, which 
poses difficulties in 
separating the individual 
Figure 1. Absorption spectra of common biological 
absorbers in the near infrared. Water and lipid values 
have been rescaled. 
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effects of each. Absorption is wavelength-dependent for each chromophore, as 
shown in Figure 1[14], while scattering decreases with increasing wavelength in 
a  power law relationship in the NIR[15].  
Given the high scattering of light in most human tissues (µs´ is typically at 
least 10 fold higher than µa in the near-infrared [NIR]), photon propagation can be 
modeled using the Boltzmann Transport Equation[13], [16]. Analytical solutions 
to the Boltzmann Transport Equation are non-trivial, and the equation is often 
simplified to the time-dependent standard diffusion equation, also called P1 
approximation[17], 
!! !" 𝒓,!!" − 𝐷𝛻!𝜑 𝒓, 𝑡 + 𝜇!𝜑 𝒓, 𝑡 = 𝑆 𝒓, 𝑡    ( 1 ) 
 
where φ is the fluence rate, S is the source, c is the speed of light in tissue, and 
 𝐷 = !!(!!!!!!)   .  ( 2 )  
The diffusion approximation can also be formulated for a point source 
sinusoidally modulated at angular frequency, ω,[17]  
𝜑 𝒓, 𝑡 = !!"!!" !"# (!!!)! + !!"!!" !"# (!!!"#$ !)! ×𝑒𝑥𝑝 [−𝑖 𝑘!"#$𝑟 − 𝜔𝑡 ] , ( 3 ) 
where Adc is the DC component of the source, Aac is the AC component of the 
source, δ is the DC penetration depth, and kreal and kimag are the real and 
imaginary parts of the photon density wave vector, respectively, which are 
defined as  
𝑘!"#$ = !! 𝜇!𝜇!′{[1+ !!!! !]!! + 1}!/!    ( 4 ) 
and 
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𝑘!"#$ = !! 𝜇!𝜇!′{[1+ !!!! !]!! + 1}!/!  . ( 5 ) 
Boundary conditions must be carefully considered in order to avoid 
discontinuities at the air-tissue boundary. For a source-detector geometry in 
reflectance mode with boundary conditions describing a semi-infinite medium 
[17], [18], the measured phase lag and amplitude attenuation are defined as  𝛳!"#(!,!) = 𝑘!"#$ 𝜔 𝑟! − 𝑎𝑟𝑐𝑡𝑎𝑛 (!"#$!"#$ )    ( 6 ) 
and 𝐴!""(𝜌,𝜔) = !!"!!" (𝑅𝐸𝐴𝐿! + 𝐼𝑀𝐴𝐺!)!/!  , ( 7 )  
where 
 𝑅𝐸𝐴𝐿= 𝑒𝑥𝑝 [−𝑘𝑟𝑒𝑎𝑙 𝜔 𝑟0𝑏]𝑟0𝑏 − 𝑐𝑜𝑠 [𝑘𝑖𝑚𝑎𝑔 𝜔 𝑟0𝑏− 𝑟0 ] 𝑒𝑥𝑝 [−𝑘𝑟𝑒𝑎𝑙 𝜔 𝑟0𝑏]𝑟0𝑏  ( 8 ) 𝐼𝑀𝐴𝐺 = 𝑠𝑖𝑛 𝑘!"#$ 𝜔 𝑟!! − 𝑟! !"# !!!"#$ ! !!!!!!  ( 9 ) 𝑟! = [(𝜇!!)!! + 𝜌!]!/! ( 10 ) 𝑟!! = [ !!!!! !!!!""!!!!"" + !!!! ! + 𝜌!]!/!  . ( 11 ) 
 
Air is the amplitude response of the instrument, and Reff is the effective reflection 
coefficient [17]. 
 A frequency domain DOSI measurement directly measures the amplitude 
attenuation and phase delay induced on the photon density waves by the tissue 
and by the instrument. In order to separate the instrument response from the 
tissue response, an additional measurement must be taken on a phantom with 
known optical properties. The known optical properties (obtained from multi-
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distance measurements) are used in a forward model, where theoretical 
amplitude and phase are calculated according to equations 6 and 7. The 
theoretical amplitude and phase at each modulation frequency are compared, 
ratiometrically or differentially, respectively, to the measured amplitude and 
phase in order to calculate calibration factors[17], [19]. These calibration factors 
are applied to the amplitude and phase from the tissue measurement, then the 
calibrated amplitude and phase are used in an inverse model, according to 
equations 6 and 7, where least-squares fitting is used to find µa and µs´ at each 
wavelength by incrementally updating initial guesses for µa and µs´ until the error 
is minimized[17]. A modified Beer-Lambert law[20], 𝜇𝑎 𝜆 = 2.303 𝜀 𝜆 𝐶 ( 12 ) 
relates µa to chromophore concentrations, where ε(λ) is the wavelength-specific 
extinction coefficient and C is chromophore concentration. A system of linear 
equations is used to determine concentrations of each chromophore of interest, 
based on calculated µa values and extinction coefficients from Zijlstra et al. [21]. 
 
Instrumentation 
  
Frequency domain DOSI may be approached by using either a single 
modulation frequency[22]–[27] or a sweep of multiple frequencies[17], [19], [28] 
in the radio frequency (RF) range. Measurement of RF signals is challenging 
given the high speed of the signals; therefore, most single modulation frequency 
systems utilize either homodyne[23], [25], [27], [28] or heterodyne[22] techniques 
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to down-convert the high frequency signal of interest by mixing it with a reference 
signal. Broad bandwidth DOSI instruments[12], [29] that utilize light sources 
modulated at numerous RF frequencies have met such challenges using a 
network analyzer—a benchtop instrument that generates and detects electrical 
signals up to the gigahertz range. Network analyzers are accurate and precise, 
but they are also expensive and have relatively large instrument footprints. A 
schematic of a network analyzer-based frequency domain DOSI system is shown 
in Figure 2, which will be considered the gold-standard instrument, referred to as 
the “benchtop DOSI system”, in this work. The size of such a system can be 
Figure 2. Benchtop DOSI overview and schematic. 
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prohibitive to accessing patients in the clinic, and the cost can range from 
$30,000 to $60,000 (based on our internal cost estimates). Although some 
analog systems have been miniaturized[20], [30], the highly sensitive RF circuitry 
makes implementation and repairs difficult. Furthermore, frequency domain DOSI 
instruments are typically slow in acquisition time compared to their CW 
counterparts, often requiring minutes to acquire a full set of data, for example, 
using multiple wavelengths modulated at a single frequency and measured at 
multiple detectors[27]. Although recent improvements have been made in data 
acquisition rates for single modulation frequency measurements[24], frequency 
sweep DOSI systems typically require 10s of seconds to acquire data at all 
wavelengths and modulation frequencies. A high-speed, broad-bandwidth, 
digital, miniaturized DOSI system would simplify the analog circuitry, while also 
reducing the cost and footprint of the device, enabling access to more patients in 
the clinic or infusion suite.  
 In order to create a digital system, both the signal generation and 
detection functionalities of the network analyzer must be replaced. Past work has 
demonstrated the feasibility of digital signal generation and detection using direct 
digital synthesizer (DDS) integrated circuits to generated RF signals and a 3.6 
gigasample per second 2-channel analog to digital converter (ADC)[31]. This 
system relied on manufacturer evaluation boards to control the DDS and ADC 
chips, resulting in slow communication between the hardware and control 
software. Furthermore, the high sampling rate of the ADC resulted in lengthy 
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data transfer times. A second implementation of a digital system tested the 
feasibility of utilizing a slower ADC, sampling at only 25 megasamples per 
second[32]. Although signals were generated at up to 400 MHz, undersampling 
was successfully employed; given that the modulation frequency was always 
known, the aliased signal could be identified in the baseband. This 
implementation, again, relied on manufacturer evaluation boards, and a 
measurement consisting of a frequency sweep at a single wavelength took 8 
minutes. In order for a digital DOSI (dDOSI) system to be practical for clinical 
measurements, data acquisition rates must be drastically increased, all hardware 
components must be fully integrated, and the overall footprint and cost of the 
device must be reduced.  
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Specific Aims 
 
Aim 1: Complete system design and fabrication of hardware and software for 
high-speed dDOSI system.  A custom motherboard containing a 2-channel 250 
mega-sample per second (MSPS) ADC and DDS daughterboards were 
previously designed and fabricated by our group. These boards require testing 
and integration with optical components, RF components, and user software prior 
to clinical use. The instrument will utilize wavelength multiplexing, such that 
lasers (up to 6 spanning the NIR) can be modulated simultaneously and 
frequencies between 50 and 400 MHz can be swept. A Matlab-based graphical 
user interface will allow the user to set modulation parameters, iterate 
measurements, and visualize amplitude and phase data. Algorithms will be 
implemented to process multiplexed amplitude and phase data.  
Aim 2: Quantify dDOSI performance compared with gold-standard system.  
Signal-to-noise ratio and measurement acquisition timing will be determined for 
the dDOSI system. Precision over time will be determined by performing drift 
tests, and dDOSI accuracy will be compared with that of a gold-standard 
benchtop DOSI system. Tissue-simulating phantom optical properties will be 
extracted and compared with those taken at comparable wavelengths and 
modulation frequencies using the benchtop DOSI system. 
Aim 3: Validate in vivo measurement performance.  Forearm cuff occlusion 
measurements will be used to determine the ability of the dDOSI system to 
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detect changes in oxyhemoglobin and deoxyhemoglobin concentrations. Given 
that the dDOSI system will acquire measurements at a rate of tens of 
milliseconds per acquisition, it will be determined if there are detectable changes 
in optical properties and chromophore concentrations throughout the cardiac 
cycle. Finally, measurements will be taken on a healthy volunteer to ensure that 
physiologically relevant chromophore values can be extracted in the breast.  
12 
Aim 1 Results: System Development 
 
The dDOSI system has been designed such that high-speed, broad 
bandwidth, frequency domain measurements can be taken using digital signal 
generation and detection, allowing for improved system portability and lower 
instrument cost. The current implementation of the dDOSI instrument consists of 
six laser diode wavelengths spanning the NIR range, utilizing either compact, 
fiber-coupled laser diode modules or lager, fan-cooled laser diode modules. 
Lasers are driven with a DC current generated either by miniaturized current 
Figure 3. dDOSI system schematic. 
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source modules or by a standard, precision current controller. Light sources are 
modulated simultaneously with RF currents up to 400 MHz generated by DDS 
boards. The multiplexed optical signals are detected with an avalanche 
photodiode (APD), and a 2-channel ADC samples the electrical output of the 
measurement and reference channels at 250 MSPS. A schematic of the system 
is shown in Figure 3 and will be explained in detail in the following sections.  
 
Hardware Integration  
 
Previous implement-
tations[31], [32] of the dDOSI 
system utilized evaluation 
boards to control the DDS and 
ADC chips, which resulted in 
inefficient software-hardware 
communication and slow 
measurements. In 2013 the core electronics of the dDOSI system (Figure 4) 
were integrated into a single motherboard to generate and sample RF signals 
and to communicate with and transfer data to the host computer, as outlined in 
Figure 5. A development board (ZedBoard, MircoZed Zynq-7010 SoC) contains 
an ARM Cortext-A9 processor in an Artix 7 FPGA fabric, 1 GB of RAM to store 
data read from the ADC, and a Linux server to transfer data between the board 
and host computer. The user sets the desired frequency sweep settings in 
Figure 4. dDOSI system core electronics.  
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software and the Linux server configures the DDS boards accordingly. The two-
channel ADC samples data simultaneously and transfers data to the RAM on the 
MicroZed module via a parallel low voltage differential signal bus. Data are then 
transferred from the Linux server to the host computer via an Ethernet link at a 
rate of up to 170 Mbps. This fully integrated hardware system allows for rapid 
data acquisition such that fast physiological changes can be detected with the 
dDOSI system. The primary hardware is housed in a box measuring 10x12x6 
inches.  
 
 
 
 
From	
APD 
 
Figure 5. dDOSI hardware overview. Image provided by 2013 senior design group. 
15 
Sources     
 
The dDOSI system utilizes NIR laser diodes with wavelengths of 658, 690, 
785, 808, 830, and 850 nm. Blood is a primary absorber in biological tissue, and 
given that the absorption of oxy- and deoxyhemoglobin are low in the NIR region 
compared with other wavelengths (Figure 1), NIR light is able to propagate 
relatively deep into tissue. The particular wavelengths used in the dDOSI system 
allow for accurate recovery of oxy- and deoxyhemoglobin concentrations, 
however in order to reliably measure other chromophores, such as water or lipid, 
additional laser diodes should be added near the water (970 nm) and lipid (920 
nm) peaks in the absorption spectrum. The dDOSI system utilizes either 
miniaturized laser diode modules (Blue Sky Research, Fibermax) that are 
portable for clinical use, or larger laser diode modules (ThorLabs, LDM9T) 
typically employed with the benchtop DOSI system. All laser diodes are coupled 
to a single fiber bundle consisting of 400 µm fibers in a single housing.  
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Each laser diode is driven with a DC current, which is mixed with an RF 
current at a bias-tee to modulate the light. The DC current source used with the 
benchtop DOSI system is an 8-channel, high-stability laser diode controller (ILX 
Lightwave, LDC-390, Newport Corporation). The fully miniaturized dDOSI system 
utilizes smaller laser diode driver modules (LDD200-2P, Wavelength Electronics, 
Bozeman, MT, Figure 6) that can output up to 200 mA DC current and be easily 
incorporated to the dDOSI housing for portability in the clinical setting. Additional 
specifications for the miniaturized laser diode driver modules are shown in Table 
1. Custom printed circuit boards (PCB) were designed to control the miniaturized 
laser diode driver modules, as shown in Figure 6. Each laser diode driver module 
contains a modulation input pin, which allows the output current to vary inversely 
Figure 6. Miniature current controller module and example of custom PCB used to control a 
single module. The complete PCB controls all six current controller modules. 
Current output 0 to 200 mA
Supply voltage +5 to +12 V
Noise and ripple (rms) < 5 µA
Power dissipation, 25˚C 1 W
Laser Diode Driver Specifications
Table 1. Miniaturized laser diode driver specifications 
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with the voltage applied to the modulation input pin. The voltage to the 
modulation input pin is set by a simple voltage divider circuit. The custom PCB 
contains a MOSFET-controlled circuit that allows the current to switch from a 
warming current (10 mA) to a lasing current (50–100 mA, wavelength dependent) 
using a digital I/O controlled in software. The setup for the fully miniaturized 
dDOSI incorporates both the miniaturized current controller modules and the 
miniaturized laser diode modules. Some data were collected with the fully 
miniaturized system, however the majority of the dDOSI measurements 
presented will utilize the ILX Lightwave laser diode driver and the benchtop 
lasers, unless otherwise noted. Further investigation into safety components to 
protect the laser diodes from transient currents will allow for future 
implementation of the fully miniaturized system.  
 
Modulation    
 
In frequency domain DOSI measurements, each laser diode must be 
temporally intensity modulated in 
the RF range. The benchtop 
DOSI system relied on a network 
analyzer (Agilent Technologies, 
E5061B ENA Series) to output RF 
current in discrete steps from 50 
Max internal clock speed 1 GSPS
External clock speed 25 MHz
Max analog output frequency 400 MHz
Frequency resolution 0.23 Hz
DAC bit-depth 14
Typical full-scale output current 20 mA
Power consumption 715 mW
DDS Specifications
Table 2. Direct digital synthesizer (DDS) 
specifications. 
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to 500 MHz to modulate each laser diode. The dDOSI system replaces the RF 
current output functionality of the network analyzer by implementing six DDS 
chips (AD9910, Analog Devices) on individual daughterboards. Manufacturer 
specifications of DDS chips are presented in Table 2. Each DDS can output up to 
20 mA of current modulated up to 400 MHz. In the dDOSI system, the 
modulation frequencies utilized are typically between 50 and 300 MHz or 
between 50 and 400 MHz, depending on the optical attenuation of the sample 
(higher modulation frequencies may be lost in the noise floor in more attenuating 
samples) and data acquisition rate requirements. The frequency step size can be 
set between 1 MHz and 7 MHz. For high-speed measurements, the user may 
choose 7 MHz steps to optimize the temporal resolution of frequency sweeps, or 
for slower measurements the user may choose 1 MHz steps to optimize 
frequency resolution.  
A primary benefit of using DDS boards instead of the network analyzer as 
the RF current source is the ability to multiplex the laser diodes. The network 
analyzer has a single output channel, such that when using the benchtop DOSI 
system each laser is switched on sequentially and frequency sweeps are 
performed individually at each wavelength. This results in a total measurement 
time of approximately 10–15 seconds to modulate 6 lasers diodes at all 
frequencies of interest, where much of the measurement time is spent on 
switching between lasers. In contrast, since there are 6 individual DDS chips in 
the dDOSI system, laser diodes are turned on simultaneously and modulated at 
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offset frequencies. The multiplexed data is then decoupled in the frequency 
domain. A typical dDOSI measurement, for example, may sweep through 
frequencies between 50 and 400 MHz in steps of 1 MHz with the modulation 
frequency for each wavelength offset by 10 MHz. This multiplexing reduces 
measurement speed to typically less than 100 ms per frequency sweep, allowing 
for detection of rapid physiological changes. 
The RF current output of each DDS board is low-pass filtered at 400 MHz 
then routed to a 7:1 directional coupler. The majority of the output from the 
directional coupler is routed to a bias tee where it is combined with the DC 
current, such that the RF current with a DC offset is used to drive the laser. The 
lesser output from each directional coupler is used as a reference channel. All 
reference channels are routed to a power splitter/combiner (Mini-Circuits, ZBSC-
615+), such that all reference channels are detected simultaneously at one 
channel of the ADC.  
 
Detection     
 
The standard dDOSI 
configuration is a reflectance 
mode measurement (Figure 7) 
with the source fiber bundle 
and active area of an APD 
Figure 7. Source-detector configuration in 
reflectance mode. 
Fiber 
holder 
APD 
20 
placed directly on the surface of the tissue or phantom at a source detector 
separation of 15 to 30 mm. The APD module (Hamamatsu C5658) has a 0.5 mm 
active area, 2.50 x 105 V/W photoelectric sensitivity, and a high band cutoff of 1 
GHz, and contains a bias power supply and low-noise amplifier within a compact 
package.  
The electrical output of the APD is high-pass filtered at 41 MHz and routed 
to one channel of the 2-channel 
ADC (Table 3), while the 
combined reference signal from 
the power combiner is routed to 
the other channel of the ADC. At 
each frequency step, the ADC 
typically collects 4096 samples on each channel of the ADC. If the user wishes to 
lower the noise floor, more samples can be collected (i.e. 8192, 16,384…2n), but 
increasing the number of samples per step substantially increases data transfer 
and processing time. Both channels of the ADC run off of the same clock, which 
allows them to sample simultaneously with a high level of precision. Each 
channel samples at 250 MSPS.  
 
Signal Processing     
 
All signal processing is performed in Matlab (R2014b, Mathworks Natick, 
MA). The two-channel ADC samples at 250 MSPS, which, for the up to 400 MHz 
Bit-depth 14 bit
Full scale input voltage 2 Vpp
Max sampling rate 250 MSPS
Power consumption 1.25 W
ADC Specifications
Table 3. Analog to digital converter (ADC) 
specifications 
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modulation frequencies used in the dDOSI system, is less than the Nyquist 
criterion requiring a sampling rate of at least twice the bandwidth of the signal of 
interest to avoid aliasing. All signals modulated above 125 MHz are aliased; 
however, given that the exact modulation frequency is known for each 
wavelength at each frequency step, the signal of interest can be located in the 
baseband, as shown in Figure 8. The processing algorithm eliminates modulation 
frequencies that are multiples of the Nyquist frequency, then maps all measured 
(aliased) frequencies in the baseband to the corresponding original modulation 
frequencies, and removes any frequency steps at which the modulation 
frequencies for multiple wavelengths are aliased to the same frequency in the 
baseband (i.e. with a Nyquist frequency of 125 MHz, signals at 120 and 130 MHz 
would both be read as 120 MHz, and thus both frequency steps would be 
eliminated from processing). 
 
Figure 8. Example of undersampling signal detection. With a modulation frequency of 
200 MHz and a sampling rate of 250 MSPS, the signal of interest is aliased at 50 MHz. 
fs, sampling frequency; fN, Nyquist frequency. 
Baseband 1st Nyquist Zone 2nd Nyquist Zone 
fs fN 
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A fast Fourier transform (FFT) with a rectangular window is performed at 
each frequency step for the reference and measurement channels. The 
appropriate frequency bin is located for each wavelength at each modulation 
frequency step. The magnitude of the FFT of the measurement channel relative 
to that of the reference channel is considered the raw amplitude value, and, 
similarly, the phase offset between the measurement and reference channels is 
considered the raw phase value.  
 
Measurement Calibration     
 
The raw amplitude and phase reflect the amplitude attenuation and phase 
delay induced both by the tissue and by the instrument itself. In order to remove 
the instrument response, a measurement is taken on a silicone phantom with 
known optical properties. An analytical solution to the P1 approximation of the 
Boltzman Transport Equation with boundary conditions for semi-infinite 
geometry[17] is employed to calculate the forward model for the phantom 
measurement, which provides the theoretical amplitude attenuation and phase 
shift for the given optical properties and source-detector separation at each 
modulation frequency. Calibration factors for amplitude and phase are 
determined by ratiometrically or differentially comparing the measured amplitude 
and phase, respectively, to the theoretical amplitude and phase from the forward 
model. These calibration factors are then applied to the raw amplitude and phase 
measurements in order to obtain calibrated amplitude and phase, which consider 
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only the effect of the tissue. A Matlab script developed by Prof. Bruce Tromberg’s 
research group at the Beckman Laser Institute is used for all measurement 
calibration, optical property recovery, and chromophore concentration 
calculation. 
 
Optical Property and Chromophore Recovery     
 
The calibrated amplitude and phase measurements are used in an inverse 
model to approximate absorption (µa) and scattering (µs´) parameters at each 
wavelength. µa and µs´ are input into an analytical solution to the P1 diffusion 
approximation of Boltzman Transport Equation, then least-squares fitting is 
employed to minimize the error between the back-calculated and measured 
calibrated amplitude and phase[17].  
Chromophore extinction coefficients are obtained from Zijlstra et al. [21]. A 
modified version of Beer’s Law[20] (Equation 12) is used to relate µa to 
chromophore concentrations. A system of linear equations is used to calculate 
individual chromophore concentrations, such that there must be at least as many 
wavelengths employed as chromophores calculated. 
 
User Interface     
 
A custom graphical user interface (GUI), shown in Figure 9, designed in 
Matlab allows the user to set the desired parameters for frequency sweeps, data 
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acquisition, and file storage. A typical clinical measurement requires the user to 
manually scan the source-detector pair across the tissue of interest in a grid 
pattern in order to create maps of tissue chromophore concentrations. 
 
 
  
Figure 9. Graphical user interface for dDOSI system 
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Aim 2 Results: System Characterization  
 
Signal to Noise  
  
Signal to noise was determined by taking an FFT during a single 
frequency step with all six laser wavelengths employed simultaneously and with 
a single laser wavelength modulated individually. Frequency steps of both 4096 
Figure 10. Signal to noise ratio. A. 6 wavelengths modulated simultaneously with 4096 
samples acquired per frequency step. Noise floor = 46.29 dBc. B. 6 wavelengths modulated 
simultaneously with 8192 samples acquired per frequency step. Noise floor = 49.23 dBc. C. 
785 nm laser modulated individually at 70 MHz with 4096 samples acquired per frequency 
step. Noise floor = 50.15 dBc. D. 785 nm laser modulated individually at 70 MHz with 8192 
samples acquired per frequency step. Noise floor = 54.48 dBc. 
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and 8192 samples per step were analyzed and the noise floor was calculated as 
the noise level, in dBc, relative to the laser with the greatest amplitude in the 
frequency domain, as shown in Figure 10. In the simultaneous measurement 
(Figure 10 A, B), the noise floor is reduced from -46.29 dBc to -49.23 dBc when 
increasing the number of samples per frequency step from 4096 to 8192. 
Similarly, in the single wavelength measurement (Figure 10 C, D), the noise floor 
is reduced from -50.15 dBc to -54.48 dBc when increasing the number of 
samples per frequency step from 4096 to 8192. Although the noise floor is lower 
with 8192, or more, samples per frequency step, acquisition time of such 
measurements was substantially slower than of those with 4096 samples per 
frequency step, and there was no improvement in accuracy of optical properties 
(accuracy of 10 measurements on 2 phantoms with 4096 samples per frequency 
step: 1.29%; accuracy with 8192 samples per frequency step: 1.85%); therefore, 
the primary measurement mode used 4096 samples per frequency step to 
optimize speed and accuracy.  
 
Amplitude and Phase Measurements 
 
Amplitude and phase were measured on a series of silicone phantoms 
using the dDOSI system with frequency sweeps from 50 to 400 MHz in steps of 1 
MHz. An example of calibrated (black) and fit (red) amplitude and phase at each 
wavelength is shown in Figure 11. Data were calibrated using silicone phantoms 
with known optical properties in order to remove the instrument response. The  
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Figure 11. Amplitude (in arbitrary units, A.U.) and phase measured with dDOSI system at 
each wavelength. Red lines are calibrated data and black lines are model fits. 
Amplitude Phase 
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calibrated data were then fit using least-squares minimization for the P1 diffusion 
approximation of the Boltzman Transport Equation.   
Figure 12 shows an example of calibrated data (black) and fit data (red) 
for both the fully miniaturized dDOSI system (i.e. fiber-coupled laser diode 
modules and portable current controller modules) and the benchtop DOSI system 
at 658 nm. For this example, amplitude and phase were compared for frequency 
sweeps from 50 to 400 MHz at 658 nm using both the benchtop DOSI system 
and the fully miniaturized dDOSI system. The dDOSI frequency sweep used 7 
MHz steps, while the benchtop system used approximately 1 MHz steps. Data 
were calibrated using silicone phantoms with known optical properties in order to 
remove the instrument response. The calibrated data were then fit using least-
squares minimization for the P1 diffusion approximation of Boltzman Transport 
Equation.  
The fully miniaturized system performed well in initial testing, however the 
laser diode modules used were easily overdriven, possibly due to transient 
current spikes from the current controller modules or extreme sensitivity of the 
laser diodes. Additional safety components will be added to the current controller 
module PCB, and further testing will be performed to ensure that the fully 
miniaturized system is robust enough for clinical use.  
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Figure 12. Amplitude (in arbitrary units, A.U.) and phase measured with fully miniaturized 
dDOSI system compared with benchtop system at 658 nm with 15 mm source-detector 
separation. Black lines represent calibrated data (i.e. instrument response removed) and red 
lines represent fits to the P1 diffusion approximation of the Boltzman Transport Equation. 
 
Accuracy of Optical Properties 
  
Optical properties were measured for 10 silicone phantoms with varying 
amounts of titanium dioxide and nigrosin, as the scattering and absorbing agents, 
respectively, using both the dDOSI and benchtop DOSI systems. For each 
phantom, 10 frequency domain measurements were taken with each system with 
a 15 mm source-detector separation and all six wavelengths modulated at 
frequencies between 50 and 400 MHz with 1 MHz frequency steps. 4096 
samples were collected at each frequency step for the dDOSI system. Table 4 
summarizes the mean optical properties measured with each system for each 
wavelength, showing the percent difference in optical properties between 
systems. For phantom #10 measurements at 658, 690, and 850 nm were 
30 
excluded due to phase errors resulting from low detected signal levels. The mean 
of the absolute difference in optical properties for all measured phantoms 
between the two systems was 5.3% and 5.5% for µa and µs´, respectively; when 
frequency sweeps from 50–300 MHz were used, the mean accuracy in optical 
properties measured with the two systems was 4.9% and 6.0% for µa and µs´, 
respectively.  
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Table 4. Optical properties measured with dDOSI and benchtop DOSI systems. Optical 
property values are mean ± standard deviation for 10 measurements. 
phantom wavelength	(nm)
dDOSI benchtop dDOSI benchtop μa μs'
1 658 0.022	±	0.0006 0.023	±	0.0004 0.580	±	0.010 0.627	±	0.010 -3.6 -7.5
690 0.019	±	0.0004 0.020	±	0.0011 0.584	±	0.007 0.636	±	0.025 -3.2 -8.2
785 0.012	±	0.0001 0.013	±	0.0001 0.534	±	0.003 0.588	±	0.004 -6.9 -9.2
808 0.011	±	0.0001 0.011	±	0.00005 0.510	±	0.004 0.561	±	0.002 -6.0 -9.2
830 0.010	±	0.0001 0.011	±	0.00003 0.480	±	0.002 0.544	±	0.003 -6.3 -11.7
850 0.010	±	0.0004 0.010	±	0.00005 0.479	±	0.014 0.539	±	0.001 -5.2 -11.1
2 658 0.021	±	0.0007 0.021	±	0.0003 0.611	±	0.014 0.653	±	0.006 -1.2 -6.5
690 0.018	±	0.0002 0.019	±	0.0007 0.616	±	0.007 0.645	±	0.018 -4.5 -4.5
785 0.010	±	0.0001 0.011	±	0.0001 0.569	±	0.003 0.619	±	0.003 -6.6 -8.1
808 0.009	±	0.0001 0.009	±	0.0002 0.554	±	0.003 0.600	±	0.010 -4.5 -7.7
830 0.008	±	0.0001 0.009	±	0.00005 0.530	±	0.002 0.584	±	0.002 -6.6 -9.2
850 0.007	±	0.0003 0.008	±	0.00005 0.530	±	0.011 0.581	±	0.001 -6.5 -8.7
3 658 0.021	±	0.0006 0.022	±	0.0003 0.904	±	0.014 0.942	±	0.010 -6.6 -4.0
690 0.018	±	0.0005 0.019	±	0.0003 0.891	±	0.013 0.922	±	0.009 -6.2 -3.4
785 0.010	±	0.0001 0.011	±	0.0001 0.820	±	0.002 0.882	±	0.002 -8.0 -7.0
808 0.009	±	0.0001 0.010	±	0.0001 0.798	±	0.006 0.859	±	0.003 -7.3 -7.0
830 0.008	±	0.00004 0.009	±	0.00002 0.776	±	0.001 0.848	±	0.002 -9.2 -8.5
850 0.007	±	0.0004 0.008	±	0.00004 0.772	±	0.020 0.844	±	0.001 -8.8 -8.6
4 658 0.004	±	0.0001 0.004	±	0.0001 1.348	±	0.007 1.358	±	0.004 1.1 -0.7
690 0.004	±	0.0001 0.004	±	0.00004 1.288	±	0.007 1.285	±	0.005 -1.8 0.3
785 0.002	±	0.00001 0.002	±	0.00002 1.096	±	0.001 1.110	±	0.003 0.2 -1.3
808 0.002	±	0.00003 0.002	±	0.0001 1.052	±	0.004 1.062	±	0.003 9.4 -0.9
830 0.001	±	0.00001 0.001	±	0.00001 1.021	±	0.001 1.036	±	0.003 1.9 -1.4
850 0.001	±	0.0001 0.001	±	0.00003 1.008	±	0.009 1.023	±	0.001 0.2 -1.5
5 658 0.017	±	0.0005 0.017	±	0.0002 0.717	±	0.012 0.726	±	0.005 1.3 -1.2
690 0.014	±	0.0003 0.015	±	0.0003 0.706	±	0.008 0.700	±	0.011 -1.8 0.8
785 0.007	±	0.0001 0.008	±	0.00005 0.634	±	0.002 0.649	±	0.002 -2.8 -2.3
808 0.006	±	0.0001 0.006	±	0.0001 0.614	±	0.005 0.616	±	0.003 2.3 -0.3
830 0.006	±	0.00003 0.006	±	0.00003 0.586	±	0.001 0.601	±	0.002 2.2 -2.6
850 0.005	±	0.0002 0.005	±	0.00005 0.582	±	0.009 0.594	±	0.001 2.2 -1.9
6 658 0.043	±	0.0023 0.047	±	0.0003 0.582	±	0.031 0.594	±	0.003 -8.8 -1.9
690 0.040	±	0.0005 0.041	±	0.0019 0.550	±	0.007 0.601	±	0.028 -1.4 -8.4
785 0.024	±	0.0002 0.025	±	0.0002 0.511	±	0.003 0.557	±	0.003 -5.0 -8.4
808 0.021	±	0.0003 0.022	±	0.0002 0.503	±	0.007 0.544	±	0.005 -5.8 -7.5
830 0.021	±	0.0001 0.021	±	0.0001 0.455	±	0.002 0.512	±	0.002 -3.5 -11.3
850 0.019	±	0.0008 0.020	±	0.0001 0.455	±	0.017 0.519	±	0.001 -3.1 -12.4
7 658 0.050	±	0.0024 0.053	±	0.0027 0.399	±	0.025 0.424	±	0.028 -5.9 -5.8
690 0.042	±	0.0013 0.044	±	0.0036 0.419	±	0.014 0.453	±	0.044 -4.2 -7.6
785 0.024	±	0.0003 0.026	±	0.0001 0.411	±	0.006 0.452	±	0.002 -7.3 -9.1
808 0.021	±	0.0006 0.023	±	0.0001 0.407	±	0.011 0.442	±	0.003 -8.3 -8.0
830 0.020	±	0.0002 0.022	±	0.0001 0.367	±	0.004 0.418	±	0.004 -7.1 -12.2
850 0.017	±	0.0043 0.020	±	0.0001 0.309	±	0.128 0.425	±	0.001 -16.0 -27.5
8 658 0.009	±	0.0001 0.009	±	0.0001 0.874	±	0.006 0.871	±	0.006 -1.1 0.3
690 0.010	±	0.0002 0.010	±	0.0003 0.859	±	0.011 0.857	±	0.013 -1.0 0.3
785 0.008	±	0.00005 0.008	±	0.0001 0.815	±	0.002 0.814	±	0.002 -0.5 0.2
808 0.006	±	0.0002 0.006	±	0.0002 0.836	±	0.009 0.834	±	0.009 -1.0 0.3
830 0.004	±	0.00001 0.004	±	0.00002 0.831	±	0.001 0.829	±	0.001 -1.2 0.2
850 0.004	±	0.00005 0.004	±	0.00005 0.827	±	0.002 0.824	±	0.002 -1.5 0.4
9 658 0.003	±	0.0001 0.003	±	0.0001 1.375	±	0.005 1.418	±	0.012 -6.8 -3.1
690 0.002	±	0.00004 0.003	±	0.0001 1.286	±	0.006 1.327	±	0.012 -9.5 -3.1
785 0.001	±	0.00002 0.002	±	0.00004 1.079	±	0.003 1.120	±	0.003 -18.5 -3.7
808 0.001	±	0.00003 0.001	±	0.0001 1.054	±	0.004 1.089	±	0.005 -15.9 -3.2
830 0.001	±	0.00003 0.001	±	0.00002 1.006	±	0.002 1.039	±	0.004 -16.1 -3.2
850 0.001	±	0.0002 0.001	±	0.00002 0.975	±	0.023 1.027	±	0.001 5.8 -5.0
10 785 0.034	±	0.0001 0.034	±	0.0002 0.891	±	0.003 0.891	±	0.004 0.9 0.0
808 0.033	±	0.0006 0.032	±	0.0004 0.854	±	0.014 0.864	±	0.009 2.2 -1.2
830 0.028	±	0.0002 0.027	±	0.0001 0.834	±	0.005 0.833	±	0.003 0.7 0.0
μa	(mm
-1) μs´	(mm
-1) %	difference
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Figures 13 and 14 show Bland-Altman[33] plots for µa and µs´ measured 
with the dDOSI and benchtop DOSI systems, where the differences between 
optical properties with the dDOSI and benchtop system are plotted on the y-axis 
versus average optical properties for each system on the x-axis, for each 
wavelength and phantom. Nearly all values fall within 1.96 standard deviations of 
the mean difference, indicating acceptable precision between the two systems. 
µa and µs´ both tend to skew slightly lower for the dDOSI system compared to the 
benchtop DOSI system. Figures 15 and 16 show scatterplots of optical properties 
measured with each system. µa values had the best agreement between systems 
when the mean absorption coefficient was less than .015 mm-1, while µs´ had the 
best agreement between systems when the mean reduced scattering coefficient 
was greater than 1 mm-1. In healthy breast tissue µa in the NIR is typically less 
than 0.01 mm-1, and µs´ in the NIR is typically greater than 0.8 mm-1  [34]; 
therefore, the dDOSI system is likely to be capable of extracting accurate optical 
properties in physiological range for breast tissue. 
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Figure 13. Bland-Altman plots showing the difference in µa measured by the dDOSI system 
and the benchtop DOSI system plotted against the mean for 10 measurements on each of 
10 silicon phantoms with varying optical properties using the two systems. Top and bottom 
dashed lines represent 1.96 standard deviations from the mean difference (center dashed 
line). 
 
Figure 14. Bland-Altman plots showing the difference in µs´ measured by the dDOSI system 
and the benchtop DOSI system plotted against the mean for 10 measurements on each of 
10 silicon phantoms with varying optical properties using the two systems. Top and bottom 
dashed lines represent 1.96 standard deviations from the mean difference (center dashed 
line). 
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Figure 15. Scatterplot of µa measured with the dDOSI and benchtop systems, each utilizing 
modulation frequencies between 50 and 400 MHz with 1 MHz steps. 10 measurements were 
taken on each of 10 phantoms using each system. Gray line represent a linear fit, described 
by the given equation and R2. 
 
 
Figure 16. Scatterplot of µs´ measured with the dDOSI and benchtop systems, each utilizing 
modulation frequencies between 50 and 400 MHz with 1 MHz steps. 10 measurements were 
taken on each of 10 phantoms using each system. Gray line represent a linear fit, described 
by the given equation and R2. 
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  The fully miniaturized dDOSI system, which includes compact fiber-
coupled laser diode modules and portable current controller modules, underwent 
preliminary testing. Optical properties were measured for phantom #5 (Table 4) 
in a series of 5 measurements using the 658 nm laser diode modulated with a 
frequency sweep from 50–400 MHz with steps of 7 MHz and a 15 mm source-
detector separation, then compared to optical properties measured with the 
benchtop DOSI system. Mean and standard deviation of measurements with 
each system are shown in Table 5.   
 
Table 5. Optical properties at 658 nm using the fully miniaturized dDOSI system compared 
with the bencthtop DOSI system. 5 consecutive measurements were taken with each 
system. Optical property values are mean ± standard deviation. 
 
Precision Validation 
  
Neoadjuvant chemotherapy infusions in the protocol used by our group at 
Boston Medical Center typically last approximately two hours, and the dDOSI 
system will be used to take measurements at various time points throughout an 
infusion. Thus, the stability of amplitude, phase, and optical properties has been 
characterized during a two-hour drift test. Measurements were taken at 
approximately one-minute intervals on a silicone optical phantom (phantom #5, 
Table 4) using 690, 785, 808, 830, and 850 nm lasers modulated simultaneously 
dDOSI benchtop %	difference
µa	(mm
-1) 0.0178	±	0.0002 0.018	±	0.0001 -1.71
µs´	(mm
-1) 0.707	±	0.006 0.737	±	0.008 -4.14
36 
in frequency sweeps from 50–400 MHz with a 15 mm source-detector 
separation. Amplitude and phase were examined for the duration of the drift test 
for the 808 nm laser modulated at 50 MHz and were plotted in Figures 17 and 
18. For this wavelength and modulation frequency, phase drift had a standard 
deviation of 0.54 degrees and amplitude drift had a standard deviation of 0.89%. 
 
Figure 17. Phase measurements for 808 nm laser diode modulated at 50 MHz during a two-hour 
drift test with measurements taken approximately every minute. 
 
 
Figure 18. Amplitude measurements for 808 nm laser diode modulated at 50 MHz during a two-
hour drift test with measurements taken approximately every minute. 
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 System stability was further analyzed for all wavelengths and modulation 
frequencies used in the drift test, as shown in Table 6. Amplitude and optical 
property stability were defined as the standard deviation divided by the mean at 
each modulation frequency, averaged for all wavelengths. Phase stability was 
defined as the standard deviation throughout the drift test averaged for all 
wavelengths and modulation frequencies. Although there was somewhat 
increased variability in amplitude and phase when examining all wavelengths and 
modulation frequencies, rather than a single wavelength and modulation 
frequency, the stability in µa and µs´ was 2.65% and 1.34%, respectively, 
throughout the drift test. The good stability in optical properties was likely 
influenced by the large range of modulation frequencies used to fit the diffusion 
model.  
 
Table 6. System stability during 2-hour drift test. 
 
Speed 
  
Previous frequency domain DOSI instruments[17], [32] have performed 
frequency sweeps with each wavelength modulated individually in a sequential 
manner. The dDOSI system, however, utilizes wavelength multiplexing, which 
amplitude 2.7%
phase 3.8˚
µa 2.6%
µs´ 1.3%
Average stability across all wavelengths and modulation frequencies
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eliminates switching time between lasers and reduces data acquisition time, 
resulting in the ability to measure fast physiological changes. The rate at which 
frequency sweep measurements can be performed is dependent on the range of 
modulation frequencies and the number of discrete steps used. Table 7 shows 
the rate at which physiological changes can be detected, using various frequency 
ranges and step sizes. The maximum speed achieved with frequency sweep 
(50–300 MHz) measurements with the dDOSI system was 97.2 Hz, which is fast 
enough to detect physiological changes at the cardiac rate with good temporal 
resolution.  
 
Table 7. Frequency sweep measurement rates. 
  
In order to test the maximum measurement speed attainable with the 
dDOSI system, measurements were also taken with a single modulation 
frequency. When modulating at only 50 MHz, a measurement rate of 2557 Hz 
can be achieved. Although this is not the preferred data acquisition mode, 
because utilizing additional modulation frequencies improves model fit accuracy, 
it provides a useful comparison to other frequency domain systems which utilize 
a single modulation frequency[22]–[27].   
Range Step size Measurement time (ms) Measurement rate (Hz)
1 MHz 71.9 13.9
7 MHz 10.3 97.2
1 MHz 102 9.78
7 MHz 14.7 68.1
50 - 300 
MHz
50 - 400 
MHz
Frequency Sweep Measurement Speeds
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Aim 3 Results: In vivo Testing 
 
Cuff Occlusion Measurement 
  
In vivo testing was performed in order to verify that acquired optical 
properties yielded physiologically appropriate chromophore values. The first in 
vivo measurement was a cuff occlusion in which a blood pressure cuff was 
placed on the upper arm and optical measurements were taken on the forearm of 
a 27-year-old female volunteer. The cuff was loosely secured in order to measure 
baseline levels of oxy- and deoxyhemoglobin then was inflated to 260 mmHg for 
approximately 3 minutes. The cuff was released and data were acquired for 
approximately 3 additional minutes. Frequency sweeps between 50 and 400 
MHz, with frequency steps of 7 MHz, were used to modulate all 6 laser diodes 
simultaneously. Measurements were taken approximately every 4 seconds for 7 
minutes. Source-detector separation was set to 15 mm, and in vivo 
measurements were calibrated using a silicone phantom with known optical 
properties. Chromophore concentrations were calculated for oxy, deoxy- and 
total hemoglobin for each measurement.  
 Figure 19 shows oxy- and deoxyhemoglobin concentrations throughout 
the cuff occlusion test. At baseline average oxy- and deoxyhemoglobin 
concentrations were 46.6 and 29.7 µM, respectively. At the time of cuff release, 
oxyhemoglobin concentration had dropped to 33.6 µM and deoxyhemoglobin had 
increased to 40.1 µM. After cuff release oxyhemoglobin rebounded to a local 
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maximum of 63.0 µM and deoxyhemoglobin dropped to 18.6 µM, before both 
chromophore concentrations began to return toward their baseline values. These 
results are consistent with arterial flow reduction during cuff occlusion, followed 
by a rush of arterial blood into the forearm after cuff release. 
  
Rapid in vivo Measurements 
  
In order to test the ability of the dDOSI system to measure physiological 
changes at the cardiac rate, frequency sweep measurements were taken on the 
finger of a 27-year-old female volunteer. Measurements were taken in 
transmission mode at the base of the finger with a 15 mm source-detector 
separation. Frequency sweeps from 50–300 MHz with 7 MHz steps were used to 
modulate all 6 laser diodes simultaneously. 350 frequency sweeps were 
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Figure 19. Forearm cuff occlusion test. Cuff was occluded during time interval between 
dashed lines. 
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measured with a measurement rate of 97.1 Hz. A silicone phantom with known 
optical properties was used to calibrate amplitude and phase measurements. 
Chromophore concentrations were calculated using optical properties from the 
690, 785, 808, and 830 nm laser diodes. The analytical solution to the P1 
approximation of the Boltzman Transport Equation with semi-infinite boundary 
conditions was used to fit reflectance mode calibration phantom measurements, 
while that with infinite boundary conditions[17] was used to fit the transmission 
mode finger measurements. 
 An ECG signal was measured simultaneously with the optical signal. The 
dDOSI system was configured to output a digital sample at the beginning of each 
frequency sweep. The ECG signal and dDOSI digital signals were detected 
simultaneously on an external data acquisition board, such that the optical signal 
could be synchronized with the ECG signal. Figures 20–24 show 5-point moving 
averages of optical properties and chromophore concentrations from the finger 
transmission measurement temporally aligned with the ECG. In Figure 20, µa 
values fluctuate temporally with the cardiac cycle, likely due to increased blood 
volume in the figure after ventricular contraction. There is a lag in the upstroke of 
the µa signal after the R-wave of the ECG, given the transmission time to the 
peripheral vasculature, which typically ranges from about 200 to 300 ms from R-
wave to the upstroke of the photoplethysmographic signal measured in the 
fingertip[35]. Figure 21 shows that there is substantially less variation in µs´, 
compared with µa, throughout the cardiac cycle. 
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Figure 20. Absorption coefficient measured in the finger throughout the cardiac cycle and 
temporally aligned with an ECG. 
 
Figure 21. Reduced scattering coefficient measured in the finger throughout the cardiac 
cycle and temporally aligned with an ECG. 
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 Chromophore values were measured throughout the cardiac cycle. Arterial 
blood is oxygen-rich and has a pulsatile flow profile, while venous blood contains 
less oxygen and the flow is more constant, as compared to arterial flow. Figure 
22 shows that oxyhemoglobin concentration fluctuates at the same frequency as 
the ECG signal, suggesting that the dDOSI system is capable of detecting 
pulsatile, oxygenated, arterial blood flow. Figure 23 shows that deoxyhemoglobin 
concentration remains relatively constant throughout the cardiac cycle, given the 
lack of deoxyhemoglobin in the pulsatile arterial flow. Finally, total hemoglobin, 
shown in Figure 24, varies closely with the ECG signal, indicative of fluctuations 
in blood volume throughout the cardiac cycle.  
 
 
Figure 22. Oxyhemoglobin (HbO2) concentration measured throughout the cardiac cycle. 
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Figure 23. Deoxyhemoglobin (Hb) concentration measured throughout the cardiac cycle. 
 
 
Figure 24. Total hemoglobin concentration (THC) measured throughout the cardiac cycle. 
 
 
Chromophore Maps in Healthy Breast Tissue 
  
Optical properties of breast tissue were measured on a healthy 28-year-
old female volunteer. Measurements were taken with the dDOSI system using 
658, 690, 785, 808, 830, and 850 nm lasers with a 28 mm source-detector 
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separation and modulation frequencies from 50 to 400 MHz. 36 point 
measurements were taken in which the source-detector pair was manually 
scanned across the right breast in a 6 x 6 grid pattern with 1 cm spacing between 
measurement points. A quadrant of the areolar complex was located at the 
bottom left corner of the imaging grid, covering approximately 2 cm vertically and 
1 cm horizontally of the imaging area. Optical properties were calculated and 
chromophore values determined for each data point. Data from the 658 and 850 
nm wavelengths were excluded due to noise in the phase measurement at these 
wavelengths. Figure 25 shows chromophore maps for deoxyhemoglobin and 
total hemoglobin concentrations with linear interpolation between measurement 
points.  
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 Following the dDOSI breast measurements, an additional set of 
measurements was taken with a clinical DOSI system[30] developed by the 
Beckman Laser Institute, using the same measurement grid as was used in the 
dDOSI measurements. Chromophore maps of resulting deoxyhemoglobin and 
total hemoglobin concentrations correlated well with those shown in Figure 25.  
Figure 25. Chromophore concentrations in the right breast of a 
healthy volunteer measured using the dDOSI system. A quadrant 
of the areolar complex is located at the bottom left of the image. 
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Conclusions and Future Work 
 
 The dDOSI system has been developed in order to increase access to 
patients by simplifying the standard benchtop DOSI system. The hardware-
integrated dDOSI system utilizes direct digital signal generation and detection, 
which eliminates the need for a costly and cumbersome network analyzer. Laser 
diodes and current drivers can be miniaturized to further improve the portability of 
the system. The overall cost of the dDOSI (Appendix) system is nearly tenfold 
lower than that of the benchtop DOSI system, yet the accuracy and precision 
remain comparable to those of previous systems. By utilizing wavelength 
multiplexing, frequency sweep measurements can be taken at nearly 100 Hz, 
allowing for detection of physiological changes at the cardiac rate. These 
improvements to the DOSI platform will allow for more efficient patient 
measurements and the ability to comfortably measure patients in an infusion 
suite in order to ultimately optimize treatment regimens for those undergoing 
neoadjuvant chemotherapy.  
 Future work on the dDOSI system will involve implementing further 
stabilizing components on the PCBs that control the miniaturized laser diode 
driver modules in order to minimize transient voltage spikes. The fully 
miniaturized system with fiber-coupled laser diode modules will be rigorously 
tested to ensure reliability in clinical measurements.  
 The ability to take rapid frequency domain dDOSI measurements may 
allow for further investigation into hemodynamics, particularly examining 
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chromophore concentrations in abnormal tumor vasculature. Rapid 
measurements may also allow for future improvements in tissue scanning 
methods. Point scanning could be automated to improve speed and repeatability 
of chromophore map data acquisition.  
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Appendix. Cost of materials for fully miniaturized dDOSI system 
 
 
Designation Item 
Part Number/ 
Manufacturer Quantity Unit Cost 
Extended 
Cost 
motherboard 
and 
components 
MicroZed System-On-
Module Z7010 1 $199.00 $199.00 
4-Layer Motherboard 
PCB Advanced Circuits 1 $283.45 $283.45 
4-Layer Frequency 
Synthesizer PCB Advanced Circuits 6 $93.00 $558.00 
Direct Digital 
Synthesis Chips AD9910  6 $56.93 $341.58 
Dual Channel 
250MSPS ADC Chip ADS62P49  1 $207.97 $207.97 
Remaining DDS Parts 
(Passives + Other ICs)   6 $30.00 $180.00 
Remaining ADC Parts 
(Passives + Other ICs)   1 $92.03 $92.03 
SD Card 2Gb   1 $5.99 $5.99 
laser diodes 
Pigtail laser - 658 nm FMXL658-25YF0A 1 $394.00 $394.00 
Pigtail laser - 690 nm FMXL690-25YF0A 1 $401.00 $401.00 
Pigtail laser - 785 nm FMXL785‐50YF0A 1 $434.00 $434.00 
Pigtail laser - 808 nm FMXL808-50YF0B 1 $1,020.00 $1,020.00 
Pigtail laser - 830 nm FMXL830-40YF0B 1 $459.00 $459.00 
Pigtail laser - 850 nm FMXL850-40YF0B 1 $459.00 $459.00 
current 
controllers 
Laser diode drivers LDD200-2P 6 $77.00 $462.00 
Custom PCB Express PCB 1 $288.55 $288.55 
MOSFET 
DMN2004DMKDICT
-ND 6 $0.44 $2.64 
Op-amp 
AD8032ARZ-
REEL7CT-ND 6 $4.70 $28.21 
Capacitors BC2665CT-ND 6 $0.18 $1.08 
Potentiometers 3386P-203LF-ND 6 $1.60 $9.60 
SMA connectors WM9458-ND 6 $3.07 $18.43 
Additional connectors 
and passives (est.)   1 $50.00 $50.00 
housing 
Enclosure Box:  
Aluminum Black Bud Industries 1 $122.00 $122.00 
Enclosure SMA Feed 
Through Connectors   8 $7.50 $60.00 
SMA Cables   6 $3.49 $20.94 
    
   
  
  Grand Total    $6,098.47 
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